Tigatuzumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A humanized agonistic monoclonal antibody directed against human tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural receptor ligand TRAIL, tigatuzumab binds to TRAIL-R2, activating signal transduction pathways that may result in tumor cell apoptosis and a reduction in tumor growth. A member of the tumor necrosis factor (TNF) receptor family, TRAIL-R2, also known as DR5 (death receptor 5), is expressed on the surfaces of many types of malignant cells.

**Synonyms:** - Anti-DR5 MoAb - Anti-TRAIL-R2 MoAb - CS 1008 - CS-1008 - CS1008 - TIGATUZUMAB - anti-[Homo sapiens TNFRSF10B (Tumor Necrosis Factor Receptor Superfamily Member 10B, DR5, TRAIL-R2, CD262)] Humanized Monoclonal TRA-8